|
|
T2 Biosystems Announces Third Quarter 2022 Financial Results
|
|
|
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
|
|
|
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
|
|
|
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize
|
|
|
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule
|
|
|
T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022
|
|
|
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel
|
|
|
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
|
|
|
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
|
|
|
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
|
